Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA Stroke Trial

被引:109
|
作者
Broderick, JP
Lu, M
Kothari, R
Levine, SR
Lyden, PD
Haley, EC
Brott, TG
Grotta, J
Tilley, BC
Marler, JR
Frankel, M
机构
[1] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA
[2] Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI USA
[3] Borgess Res Inst, Kalamazoo, MI USA
[4] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[5] Univ Calif San Diego, Stroke Ctr, San Diego, CA 92103 USA
[6] Univ Virginia Hlth Syst, Dept Neurol, Charlottesville, VA USA
[7] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA
[8] Univ Texas, Dept Neurol, Houston, TX USA
[9] Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA
[10] NINDS, Div Stroke & Trauma, Bethesda, MD 20892 USA
[11] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
关键词
clinical trials; models; predictive; outcome; stroke; tissue plasminogen activator;
D O I
10.1161/01.STR.31.10.2335
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We sought to identify the most powerful binary measures of the treatment effect of tissue plasminogen activator (tPA) in the National Institute of Neurological Disorders and Stroke (NINDS) rTPA Stroke Trial, Methods-Using the Classification and Regression Tree (CART) algorithm, we evaluated binary cut points and combination of binary cut points with the 4 clinical scales and head CT imaging measures in the NINDS tPA Stroke Trial at 4 times after treatment: 2 hours, 24 hours, 7 to 10 days, and 3 months. The first analysis focused on detecting evidence of "early activity" of tPA with the use of outcome measures derived from the 2-hour and 24-hour clinical and radiographic measures, The second analysis focused on longer-term outcome and "efficacy" and used outcome measures derived from 7- to 10-day and 3-month measures. After identifying the cut points with the ability to classify patients into the tPA and placebo groups using part I data from the trial, we then used data from part II of the trial to validate the results. Results-Of the 5 most powerful outcome measures for early activity of tPA, 4 involved the National Institutes of Health Stroke Scale (NIHSS) score at 24 hours or changes in the NIHSS score from baseline to 24 hours. The best overall single outcome measure was an NIHSS score less than or equal to 2 at 24 hours, which provided an odds ratio of 5.4 (95% CI, 2.4 to 12.1) and a projected sample size of 58 per treatment group assuming an alpha of 0.05 (2-sided test) and a power of 80% using part I data. The top 2 and 3 of the top 5 outcome measures for detecting the longer-term efficacy of tPA also involved the NIHSS score. A Rankin score of 0 or 1 at 3 months was the third most powerful outcome measure. Outcome measures identified by CART from part I data were not as sensitive in detecting the effectiveness of tPA when applied to part n data. Conclusions-Measures using the NIHSS and a Rankin score less than or equal to 1 were the most sensitive discriminators of the effectiveness of tPA in the NINDS tPA Stroke Trial compared with the other clinical and radiological measures. The outcome measures identified in this exploratory analysis (eg, NIHSS score less than or equal to 2 at 24 hours) would be best used as an outcome measure in future phase II trials of recanalization begun within the first 3 hours after stroke onset, with inclusion and exclusion criteria similar to those in the NINDS tPA Stroke Trial.
引用
收藏
页码:2335 / 2341
页数:7
相关论文
共 50 条
  • [41] Quantitative Proteomic Profile of Tissue Plasminogen Activator (tPA) Responders
    Ning, MingMing
    Cao, Jing
    Lopez, Mary
    Sarracino, David A.
    McMullin, David
    Buonanno, Ferdinando S.
    Wang, Xiaoying
    Lo, Eng H.
    STROKE, 2013, 44 (02)
  • [42] Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients
    Lindgren, A
    Lindoff, C
    Norrving, B
    Astedt, B
    Johansson, BB
    STROKE, 1996, 27 (06) : 1066 - 1071
  • [43] Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: Evaluation of the NINDS rt-PA Stroke Study
    Demchuk, Andrew M.
    Khan, Firosh
    Hill, Michael D.
    Barber, Philip A.
    Silver, Brian
    Patel, Suresh
    Levine, Steven R.
    CEREBROVASCULAR DISEASES, 2008, 26 (02) : 120 - 125
  • [44] Hemi-Orolingual Angioedema After Tissue Plasminogen Activator (tPA) Administration in Acute Ischemic Stroke
    Shaikh, S.
    Lacasse, A.
    Singh, N.
    Edwards, A.
    Kumar, V
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [45] Plasma Protein Changes after Tissue Plasminogen Activator (tPA) treatment in Acute Ischemic Stroke Patients
    Ning, MingMing
    Cao, Jing
    Lopez, Mary
    Sarracino, David A.
    McMullin, David
    Walleigh, Diana
    Sena, Dayse
    Feeney, Kathleen
    Thayer, Molly
    Elia, Mikaela
    Koop, Hailey
    Buonanno, Ferdinando S.
    Wang, Xiaoying
    Lo, Eng H.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (03) : 676 - 676
  • [46] Enhanced thrombolysis using tissue plasminogen activator (tPA)-loaded PEGylated PLGA nanoparticles for ischemic stroke
    Zamanlu, Masumeh
    Eskandani, Morteza
    Barar, Jaleh
    Jaymand, Mehdi
    Pakchin, Parvin Samadi
    Farhoudi, Mehdi
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2019, 53
  • [47] Transient bullous rash following the administration of tissue plasminogen activator (TPA) in two cases of acute stroke
    Egbarya, A.
    Sabetay, S.
    River, Y.
    Abu Raya, M.
    Wasim, Z.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 411 - 411
  • [48] Utilization of intravenous tissue-type plasminogen activator (tPA) for Ischemic stroke: Does gender matter?
    Myers, Daniela
    Allen, Norrina
    Dostal, Jackie
    Sama, Danny
    Brass, Lawrence M.
    Lichtman, Judith H.
    CIRCULATION, 2006, 113 (21) : E822 - E822
  • [49] Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
    Chapman, Sherita N.
    Mehndiratta, Prachi
    Johansen, Michelle C.
    McMurry, Timothy L.
    Johnston, Karen C.
    Southerland, Andrew M.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 75 - 87
  • [50] Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA)
    Eissa, A.
    Krass, I.
    Bajorek, B. V.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 620 - 629